Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine

J Invest Dermatol. 2010 Oct;130(10):2514-6. doi: 10.1038/jid.2010.138. Epub 2010 May 27.

Authors

Christian Busch, Jürgen Geisler, Stian Knappskog, Johan R Lillehaug, Per E Lønning

PMID: 20505745
DOI: 10.1038/jid.2010.138

No abstract available

Publication types

Letter

MeSH terms

Animals
Antineoplastic Agents, Alkylating / therapeutic use*
Cyclin-Dependent Kinase Inhibitor p16 / genetics
Cyclin-Dependent Kinase Inhibitor p16 / metabolism*
Dacarbazine / therapeutic use*
Humans
Melanoma* / drug therapy
Melanoma* / mortality
Melanoma* / secondary
Predictive Value of Tests
Skin Neoplasms* / drug therapy
Skin Neoplasms* / mortality
Skin Neoplasms* / pathology
Tumor Suppressor Protein p53 / genetics
Tumor Suppressor Protein p53 / metabolism*

Substances

Antineoplastic Agents, Alkylating
Cyclin-Dependent Kinase Inhibitor p16
TP53 protein, human
Tumor Suppressor Protein p53
Dacarbazine